

Evaluation of the effect of mesenchymal bone marrow stem cells injection on chemotherapy-induced ovarian failure in female albino rats

Thesis

Submitted in partial fulfillment for the Master Degree
in Medical Physiology
(Basic Medical Science)

Presented by

Sarah Ali Abdelhameed Gouda
(M.B, B.CH)

Under supervision of

Prof. Dr. Moshira Abdelhakiim Rateb
Professor of Physiology
Faculty of Medicine - Cairo University

Prof. Dr. Hala Gabr Metwaly
Professor of Clinical Pathology
Faculty of Medicine - Cairo University

Dr. Hanan Ahmed Seddiq
Lecturer of Physiology
Faculty of Medicine - Cairo University

Faculty of Medicine
Cairo University
2014

Acknowledgement

First of all, I would like to thank ALLAH, the most merciful, for giving me the strength and patience to complete this work.

*Heartily, it is my pleasure to express my deep gratitude and sincere appreciation to **Prof. Dr. Moshira Abdelhakiim Rateb**, Faculty of Medicine, Cairo University, who honored me by the opportunity to learn from her expanded experience. No words can express my appreciation for her precious advices and meticulous supervision.*

*I am very grateful to **Prof. Dr. Hala Gabr Metwaly**, Professor of Clinical Pathology, Faculty of Medicine, Cairo University for her following the experimental part in this work. I also appreciate her help in offering facilities in her lab during performing the practical part of this work.*

*I would like also to thank **Dr. Hanan Ahmed Seddiq**, Lecturer of Physiology, Faculty of Medicine, Cairo University, for her kind help and encouragement throughout the study.*

*I wish also to express very special thanks to **Dr. Maha Hamdi Elsissy**, Lecturer of Clinical Pathology, Faculty of Medicine, Cairo University, not only for her keen supervision, guidance of work and continuous encouragement, but also for her valuable help and kind support throughout the course of the study.*

Last, but not least, I would like to thank my dear professors and my colleagues for their constant support and encouragement.

Abstract

Objectives: This study aims at shedding light on possible answers for the following questions:

1-Can mesenchymal stem cells home in the ovaries of both control and chemotherapy treated animals. 2-Is there a possible role of TNF- α in homing of stem cells.

3-If they home, do they produce their effect through differentiation into follicles themselves or through secretion of some growth factors such as IGF-I.

Method: 72 female albino rats were randomly allocated into Control group & CTX group, each group was subdivided into 3 subgroups; Control group was subdivided into: Control A which did not receive any injection during, control B1 received Ip saline injections + single Iv saline, and control B2 received Ip saline injections + single Iv MSCs injection. CTX group was subdivided into: CTX A this subgroup received repeated Ip cyclophosphamide injections only, CTX B1 received Ip cyclophosphamide injections + single Iv saline injection and CTX B2 received cyclophosphamide Ip injections + single Iv MSCs injection. a further group (donor group) of 18 female rats of the same breed were used as MSCs donors.

The Experimental protocol was lasted for 12 weeks, divided into: Conditioning time period (1 week) followed by Injection-1 period which is lasted for 2 weeks during which the animals received Ip cyclophosphamide, saline injection or no injection at all according to their subgroups. Then, monitoring-1 period (M1) which took 1 week during which all animals were monitored for serum FSH, E2 levels and vaginal smears. At the end of (M1), 6 of animals in each subgroup were randomly sacrificed to test for ovarian histopathology and level of TNF- α in first sampling point. The rest of the animals in each subgroup were injected once with either stem cells or saline Iv or nothing according to their subgroups in Injection-2 point which was followed by monitoring-2 period (M2) lasted for 8 weeks, during which serum FSH and E2 were monitored twice at the end of the 2nd week of M2 and the end of the 8th weeks of M2. at the end of the experimental protocol, in second sampling point the remaining animals were sacrificed to evaluate ovarian histopathology & the expression of ovarian IGF-1.

Results:

Migration and homing of MSCs in the ovarian stroma of both control B2& CTX B2 with gradual partial Improvement of E2 and FSH levels as well as ovarian architecture and follicular number and maturation in CTX B2, elevation of ovarian TNF- α levels In CTX group and elevation of IGF-I immunohistochemical expressions in ovarian tissues of MSCs injected rats.

Conclusion:

Injected bone marrow derived MSCs can migrate and home in the stroma of the injured ovaries, with gradual partial improvement of hormonal function, follicular number, maturation and architecture of ovaries damaged by cyclophosphamide. IGF-I can play a role in such improvement after stem cells injection in chemotherapy- induced ovarian failure. Elevated ovarian TNF- α levels may have a role in migration and attraction of stem cells in vivo.

Key words: chemotherapy induced ovarian failure - cyclophosphamide - stem cells.

Contents

	Page
Introduction and aim of the work	1
 Chapter 1: Chemotherapy-induced ovarian failure.....	3
Normal physiology of the ovary.....	3
Growth factors and ovarian physiology.....	15
Premature ovarian failure.....	17
Chemotherapy-induced ovarian failure.....	21
 Chapter 2: Stem cells.....	27
Introduction.....	27
Criteria of stem cells.....	28
Sources of stem cells.....	30
Stem cell niche (microenvironment).....	38
Identification of adult stem cells.....	39
Stem cell migration and homing.....	46
Plasticity.....	48
Stem Cell Applications in regenerative medicine and tissue engineering.....	52
MSCs therapy and its ability to repair several diseases.....	55
Materials and Methods	58
Results.....	92
Discussion.....	149
Summary and conclusion.....	168
References.....	173
Arabic summary	

List of tables

Table No.		Page
Table (1)	Surface antigen profile of MSCs.	41
Table (2)	Serum levels of E2 in (ng/L), FSH in (IU/L) and ovarian tissue homogenate levels of TNF- α in (pg/ml) in all studied groups (at the end of monitoring-1 period).	97
Tables (3)	Mean \pm SD of the number of ovarian follicles at different stages of maturation as well as the total number of follicles in all studied groups (at 1 st sampling point).	102
Table (4)	Comparison between ovarian architecture scores of each CTX subgroup (CTX A, B1 and B2) with its corresponding control subgroup (Control A, B1 and B2) respectively, (at 1 st sampling point).	106
Table (5)	Serum levels of E2 in (ng/L) and FSH in (IU/L) in all studied groups, at the end the 2 nd week of monitoring-2 period M2(a).	108
Table (6)	Serum levels of E2 in (ng/L) and FSH in (IU/L) in all studied groups, at the end the 8 th week of monitoring-2 period M2(b).	111
Table (7)	Mean \pm SD of the number of ovarian follicles at different stages of maturation as well as the total number of follicles in all studied groups (at 2 nd sampling point).	116
Table (8)	Comparison between ovarian architecture scores of each CTX subgroup (CTX A, B1 and B2) with its corresponding control subgroup (Control A, B1 and B2) respectively, (at 2 nd sampling point).	120
Table (9)	Comparison between immunohistochemical expression of ovarian tissue IGF-I of each CTX subgroup (CTX A, B1 and B2) with its corresponding control subgroup (Control A, B1 and B2) respectively, (at 2 nd sampling point).	122
Table (10)	Comparison between immunohistochemical expression of ovarian tissue IGF-I of normal control group (Control A group) and groups which received single MSCs injection (Control B2 and CTX B2). (at 2 nd sampling point)	123

Table No.		Page
Table (11)	Serum levels of E2 (ng/L) in all studied groups over the time line period of the experimental protocol.	124
Table (12)	Serum levels of FSH (IU/L) in all studied groups over the time line period of the experimental protocol.	126
Table (13)	The correlation between ovarian IGF-I and the architecture score, and between ovarian IGF-I and serum E2 (ng/L) in different studied groups. (at 2 nd sampling point)	128
Table (14)	The correlation between ovarian TNF- α (pg/ml) and architecture score in 1st sampling stage, and between ovarian TNF- α and serum E2 level in different studied groups. (at 1 st sampling point)	130

List of figures

Figure No.		Page
Figure(1)	The process of oogenesis occurs in the ovary's outermost layer.	5
Figure (2)	Schematic cross section of a healthy graafian follicle.	8
Figure (3)	Stages of follicular development.	10
Figure (4)	Chemical structure of cyclophosphamide.	23
Figure (5)	Types of stem cell division.	28
Figure (6)	Identifying Cell Surface Markers Using Fluorescent Tags	42
Figure (7)	Looking for a Needle in a Haystack: How Researchers Find Stem Cells	43
Figure (8)	Microscopic Image of Fluorescent-Labeled Stem Cell	45
Figure (9)	SPIO-labeled neural stem cells show blue spots located inside cells, suggesting presence of iron oxide particles.(Prussian-blue staining)	46
Figure (10)	Diagrammatic representation of all studied groups.	60
Figure (11)	Diagrammatic representation of the experimental protocol in all studied groups.	62
Figure (12)	Representative standard curve for rat FSH ELISA assay	66
Figure (13)	Representative standard curve for rat E2 ELISA assay	69
Figure (14)	Representative standard curve for rat TNF- α ELISA.	76
Figure (15)	Laminar air flow cabinet (Forma Scientific, USA).	83
Figure (16)	Centrifuge (Centurion Scientific, UK).	83
Figure (17)	Separation of mononuclear cells.	85

List of charts

Chart No.		Page
Chart (1a)	Evaluation of the serum levels of E2 in (ng/L) in all studied groups (at the end of monitoring-1 period).	98
Chart (1b)	Evaluation of the serum levels of FSH in (IU/L) in all studied groups, (at the end of monitoring-1 period).	98
Chart (1c)	Evaluation of the ovarian tissue homogenate levels of TNF- α (pg/ml) in all studied groups. (at 1 st sampling point)	99
Chart (2a)	Mean \pm SD of primordial and primary follicles count in all studied groups (at 1 st sampling point).	103
Chart (2b)	Mean \pm SD of secondary and antral follicles count, in all studied groups (at 1 st sampling point).	103
Chart (2c)	Mean \pm SD of mature follicles count in all studied groups (at 1 st sampling point).	104
Chart (2d)	Mean \pm SD of total number of follicles in all studied groups (at 1 st sampling stage).	104
Chart (3a)	Serum levels of E2 in (ng/L) in all studied groups, at the end the 2 nd week of monitoring-2 period M2(a).	109
Chart (3b)	Serum levels of FSH in (IU/L) in all studied groups, at the end the 2 nd week of monitoring-2 period M2(a).	109
Chart(4a)	Serum levels of E2 in (ng/L) in all studied groups, at the end of the 8 th week of monitoring-2 period M2(b).	112
Chart (4b)	Serum levels of FSH in (IU/L) in all studied groups, at the end of the of monitoring-2 period M2(b).	112
Chart (5a)	Mean \pm SD of primordial and primary follicles count in all studied groups (at 2 nd sampling point).	117
Chart (5b)	Mean \pm SD of secondary and antral follicles count in all studied groups (at 2 nd sampling point).	117
Chart (5c)	Mean \pm SD of mature follicles count in all studied groups (at 2 nd sampling point).	118
Chart (5d)	Mean \pm SD of total follicles count in all studied groups (at 2 nd sampling point).	118

List of graphs

Graph No.		Page
Graph (1)	Evaluation of the changes in the levels of the serum E2 (ng/L) in all studied groups over the time line period of the experimental protocol.	125
Graph (2)	Evaluation of the changes in the levels of the serum FSH (IU/L) in all studied groups over the time line period of the experimental protocol.	127
Graph (3)	The correlation between ovarian IGF-1 and the architecture score in all studied groups (at 2 nd sampling point).	128
Graph (4)	The correlation between ovarian IGF-1 and the level of serum E2 (ng/L) in all studied groups (at 2 nd sampling point).	129
Graph (5)	The correlation between the level of ovarian TNF- α (pg/ml) and architecture score in all studied groups (at 1 st sampling point).	130
Graph (6)	The correlation between the level of ovarian TNF- α (pg/ml) and the serum E2 level in all studied groups (at 1 st sampling point)	131
Graph(7)	Printout of flowcytometric analysis of surface markers of MSCs samples obtained from cultured plates two weeks after culturing of MSCs. Samples have shown positive expression of both CD90 and CD29 markers.	132

List of tissue sections

Section No.		Page
Section (1)	Hematoxylin and Eosin slide of ovarian tissue taken from normal control rats (control A subgroup) showing normal ovarian architecture and follicles at different stages of maturation. (x40)	133
Section (2)	Hematoxylin and Eosin slide of ovarian tissue taken from rat subjected to repeated Ip saline injections (Control B1 subgroup) showing evidence of haemorrhage (arrows).(x40)	134
Section (3)	Hematoxylin and Eosin section of ovarian tissue taken from (Control B2 subgroup) showing an evidence of haemorrhage (arrows).(x40)	134
Section (4)	Hematoxylin and Eosin section showing necrotic ovarian tissue after repeated Ip cyclophosphamide injections (CTX A subgroup).(x40)	135
Section (5)	Hematoxylin and Eosin ovarian section of a rat subjected to repeated injections of cyclophosphamide CTX B1 subgroup. (X40)	135
Section (6)	Hematoxylin and Eosin slide of ovarian tissue of a rat injected with cyclophosphamide, before MSCs treatment, showing atretic follicles (CTX B2 subgroups).	136
Section (7)	Hematoxylin and Eosin slide of ovarian tissue taken from control A subgroup showing follicles at different stages of maturation (at 2 nd sampling point) (x40)	137
Section (8)	Hematoxylin and Eosin slide of a section in ovary of a rat subjected to repeated Ip saline injections followed by single Iv saline injection (Control B1 subgroup) with no evidence of haemorrhage (at 2 nd sampling point) (x40)	137

Section No.		Page
Section (9)	Hematoxylin and Eosin slide section in ovarian tissue of a rat subjected to repeated Ip saline injections followed by single Iv MSCs injection (Control B2 subgroup at 2 nd sampling point).(x40)	138
Section (10)	Hematoxylin and Eosin slide of necrotic ovarian tissues taken from rats of (CTX A subgroup) and (CTX B1 subgroup) showing complete absence of follicles (at 2 nd sampling point). (x40)	139
Section (11)	Hematoxylin and Eosin slide of ovarian section of a rat injected with cyclophosphamide followed by single MSCs injection (CTX B2 subgroup) showing reappearance of follicles at different stages of maturation (at 2 nd sampling point). (x40)	140
Section (12)	Comparison between Graafian Follicles (arrows) of normal control (control A), saline injected (control B2), positive control (CTX A) and treated cases (CTX B2), with evidence of reappearance of graafian follicle in CTX B2 at 2 nd sampling point.	141
Section (13)	Comparison between ovarian architectures of normal control (control A) and treated cases (CTX B2) (before and after treatment) showing reappearance of grape like architecture in CTX B2 after MSCs injection denoting improvement in ovarian architecture score.	142
Section (14)	Homing of MSCs in ovarian stroma of a rat treated with MSCs (CTX B2 subgroup). (x10)	143
Section (15)	Homing of MSCs in ovarian stroma of control B2 subgroup (x10)	144
Section (16)	Positive IGF-I expression (*) in control A subgroup ovary. (x10)	145
Section (17)	Positive IGF-I expression (*) in ovarian tissue of a rat in control B1 subgroup which has received saline injection only. (x10)	145

Section No.		Page
Section (18)	Positive IGF-I expression (*) in ovarian tissue of a rat in control B2 subgroup which has received saline injections followed by single MSCs cells injection.(x100)	146
Section (19)	IGF-I expression (*) in ovarian tissue of a rat in CTX A subgroup which has received cyclophosphamide injections only. (x10)	147
Section (20)	IGF-I expression (*) in CTX B1 subgroup ovaries which has received cyclophosphamide injections followed by single saline injection.(x10)	147
Section (21)	Positive IGF-I expression (*) in ovarian tissue of a rat in CTX B2 subgroup which has received cyclophosphamide injections followed by single MSCs injection.(x10)	148

List of abbreviations

ADSCs: Adipose-derived stem cells.

Akt: is a serine/threonine-specific protein kinase, also known as Protein Kinase B (PKB) that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription and cell migration.

AMH: Anti-Müllerian hormone.

ASCs: Adult Stem Cells.

Bcl-2: B-cell lymphoma 2.

bFGF: Basic fibroblast growth factor .

BM: Bone marrow.

BMP-15: Bone morphogenetic protein-15.

BMSCs: Bone marrow- stem cells.

CAM: Cell adhesion molecules.

Caspases: Cysteine aspartate-specific proteases.

CCs: Cumulus cells.

CD: Cluster of differentiation.

CFU: Colony forming unit.

c-Kit: Mast/stem cell growth factor receptor (SCFR), also known as proto-oncogene c-Kit or tyrosine-protein kinase Kit or CD117, is a protein that in humans is encoded by the KIT gene.

CL: Corpus luteum.

COC: Cumulus–oocyte complex.

Cp: Conditioning period.

CTX: Chemotherapy.

DMEM: Dulbecco's Modified Eagle's Meduim.

DPSCs: Dental pulp stem cells.

E2: Estradiol.

ECM: Extracellular matrix.

EGF: Epidermal growth factor.

EGFR: Epidermal growth factor-receptor.

ELISA: Enzyme-linked immunosorbent assay.

EPIC: European Prospective Investigation into Cancer and Nutrition.

ESCs: Embryonic stem cells.

FACS: Fluorescence-activated cell sorting.

FGF: Fibroblast growth factor.

FSH: Follicle-stimulating hormone.

FSHR: Follicle-stimulating hormone receptor.

GDF-9: Growth Differentiation Factor-9.

GFP: Green fluorescent protein.

GnRH: Gonadotropin-releasing hormone.

GSs: Granulosa cells.

hEGCs: Human embryonic germ cells.

HGF: Hepatocyte growth factor.

HM: Homogenization medium

(HPG) axis: hypothalamic-pituitary-gonadal axis.

HSCs: hematopoietic stem cells.

ICT: International Society for Cellular Therapy

IGF-I: Insulin-like growth factor-I.

IGF-IR: Insulin-like growth factor-I receptor.

IL-6: Interleukin 6.

Ip: Intra-peritoneal.

iPs: Induced pluripotent stem cells.

Iv: Intravenous.

KL: Kit-ligand.

Klf4: Kruppel-like factor 4.

LH: luteinizing hormone.

M1:Monitoring-1 period.

M2:Monitoring-2 period.

MGCs: Mural granulosa cells.

MSCs: Mesenchymal stem cells.

NanOg: (Land of youth in Irish language). It is a transcription factor in embryonic stem cells , thought to be a key factor in maintaining pluripotency.

NGFR: Nerve growth factor-receptor.

Oct4: Octamer-binding transcription factor 4.

OD: Optical density.

OSE: Ovarian surface epithelial cells.

PBS: Phosphate buffered saline.

PCR: Polymerase chain reaction.

PDGF: Platelet-derived growth factor.

PDGFR: Platelet-derived growth factor-receptor.

PDX-1: Pancreatic specific transcription factor-1.

POF: Premature ovarian failure.

PM: Phosphoramidate mustard.

PSCs: Putative stem cells.

rpm: Round per minute

Sca-1: Stem cell antigen -1.

SCAP: Stem cells from apical papilla.

SCF: Stem cell factor.

SHED: Stem cells from human exfoliated deciduous teeth.

SOD: Superoxide Dismutase.

Sp-1: First sampling stage.

Sp-2: second sampling stage.

Sox2: (Sex determining region Y)-box 2.

SP: Side population.